Every claim, every source.

This 2024 Nature Cell Biology paper from the Madeo lab identified spermidine — a polyamine found in many foods (wheat germ, soybeans, mushrooms, aged cheeses) and produced endogenously — as the essential mediator of fasting-induced autophagy. The authors ran experiments across multiple model systems: yeast, nematodes, mouse cells, and human cell lines (U2OS osteosarcoma cells and H4 neuroglioma cells). Across all systems, blocking spermidine synthesis with the inhibitor DFMO suppressed fasting-induced autophagy — and supplementing exogenous spermidine (100 µM) rescued the autophagy response. The paper also reports human-cohort metabolomics: across multiple cohorts of fasting participants (61 to 109 volunteers per cohort, fasting durations 3 to 16 days), serum spermidine levels rose during fasting. Human PBMCs showed increased hypusination of eIF5A — a downstream effect linking spermidine to translation control and autophagy machinery. The paper's mechanistic claim is significant: spermidine is not just correlated with fasting-induced autophagy; it is required for the response to occur.

This review compares the cardiovascular benefits of eating whole sardines against taking isolated fish-oil supplements. The authors argue that whole sardines provide a "matrix" of nutrients that fish-oil capsules lack: not just EPA and DHA, but calcium, vitamin D, B12, selenium, high-quality protein, and minor compounds (taurine, coenzyme Q10) absent from purified oils. Per 100 grams of cooked sardines, the USDA database reports 24.6 g of protein, 11.5 g of total fat, 473 mg of EPA, 509 mg of DHA, 382 mg of calcium, 4.8 µg of vitamin D, 8.9 µg of B12, and 52.7 µg of selenium. The review surveys randomized trials of sardine consumption versus control diets and concludes that whole-sardine intake produces favourable changes in lipid profile, inflammation markers, and insulin sensitivity, with the additional minerals and protein doing work that omega-3 supplements alone cannot. The framing throughout is that sardines outperform fish-oil supplementation as a delivery vehicle for cardiovascular benefit.

The FDA and EPA jointly publish dietary fish-consumption guidance for the U.S. public, including specific advisory recommendations for pregnant women, breastfeeding women, women of childbearing age, and young children. Fish species are categorized into "Best Choices" (eat 2–3 servings per week), "Good Choices" (eat 1 serving per week), and "Choices to Avoid" (do not eat — high methylmercury). Sardines appear in the "Best Choices" category alongside anchovies, salmon, herring, and other small-pelagic species. The advisory provides the species-by-species mercury-content basis for these recommendations and includes guidance on portion sizing for adults and children. The 2022 update reflects ongoing review of mercury data, omega-3 dietary modeling, and population-health evidence on fish consumption patterns.

This study used data from the Canadian Study of Adolescent Health Behaviors — a national survey of 2,762 adolescents and young adults — to ask how common intermittent fasting is and whether it correlates with eating-disorder behaviors. The engagement numbers were striking: roughly 48 percent of women, 38 percent of men, and 52 percent of transgender or gender-non-conforming respondents reported practicing some form of intermittent fasting in the past 12 months. The researchers used the Eating Disorder Examination Questionnaire alongside modified Poisson regression to measure associations. Across all three gender groups, intermittent fasting in the past 12 months and the past 30 days was significantly associated with elevated eating-disorder psychopathology — disordered cognitions, restrictive behaviors, and binge-purge cycles. The pattern was strongest and most consistent in women. The authors do not claim fasting causes eating disorders; the data are cross-sectional and cannot prove direction. They argue clinicians screening young patients should treat self-reported intermittent fasting as a meaningful flag.

This randomized controlled trial enrolled 71 adults with metabolic syndrome and randomized them to a five-day modified Buchinger-style fast followed by a modified DASH diet versus DASH diet alone. Investigators measured 16S rRNA gut microbiome composition, ambulatory blood pressure, antihypertensive medication requirements, and standard cardiometabolic biomarkers at baseline, immediately post-fast, and at three months follow-up. The fasting plus DASH arm showed greater reductions in systolic blood pressure, in the requirement for antihypertensive medications, and in body-mass index at three months than the DASH-only arm. Gut microbiome analysis identified specific bacterial taxa — including changes in genera linked to short-chain fatty acid production and to microbial pathways relevant to host metabolic regulation — that responded to the fast, with changes that partly persisted into the post-fast period. The paper is one of the few human RCTs to combine a multi-day fasting intervention with comprehensive microbiome characterization and clinically meaningful blood pressure endpoints.

This Cleveland Clinic-affiliated study followed 1,403 patients who were eligible for a protein-sparing modified fast program over 5 years to answer the question the original 1970s PSMF literature could not: does the dramatic short-term weight loss persist? Of those eligible, 879 (63 percent) actually initiated PSMF; the remaining 524 (37 percent) pursued other dietary approaches and served as a comparison cohort. The 1-year outcomes were dramatic and favored PSMF: -7.6 percent body weight in the PSMF arm versus -1.8 percent in the comparison arm, a 5.8-percentage-point difference (p less than 0.01). At 3 years, PSMF still showed an advantage but smaller: -2.3 percent vs -0.9 percent, a 1.4-point difference. By 5 years, the difference had effectively disappeared: -1.4 percent vs -1.0 percent (p=0.64, not statistically significant). The proportion achieving clinically meaningful (≥5 percent) weight loss told the same story: PSMF was strongly favored at 1 and 3 years, equivalent at 5 years. The honest conclusion: PSMF produces substantial short-term weight loss with good durability through year 3, but by year 5 the advantage over conventional dietary care is gone.

The REDUCE-IT trial randomized 8,179 statin-treated adults with elevated triglycerides and either established cardiovascular disease or diabetes plus risk factors to receive 2 grams of icosapent ethyl twice daily (a purified prescription-grade EPA preparation, total daily dose 4 grams) or matching placebo. After a median follow-up of 4.9 years, the icosapent ethyl arm experienced a 25% relative reduction in the primary composite endpoint of major adverse cardiovascular events (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, or unstable angina) compared with placebo. Reductions were observed across multiple individual endpoint components, including cardiovascular death. The trial reignited debate over high-dose omega-3 cardiovascular prevention after several earlier mixed-result trials and stands as the largest, longest, and methodologically strongest RCT supporting a cardiovascular benefit from a specific EPA preparation.

This NEJM review summarizes evidence that intermittent fasting regimens — alternate-day fasting, time-restricted eating, and periodic multi-day fasts — engage a "metabolic switch" from glucose-derived energy to fat- and ketone-derived energy after hepatic glycogen is depleted, typically within 12–36 hours of fasting depending on the individual and the protocol. The authors argue that repeated exposure to this switch produces adaptive responses across organ systems, including improved insulin sensitivity, reduced inflammation, increased mitochondrial biogenesis, enhanced autophagy, and improved stress resistance in cells. The review compiles findings from animal models alongside the available human trials at the time of publication. The review notes that, despite preclinical signals being strong and consistent, the human evidence base is more heterogeneous: the largest gains in metabolic markers (fasting insulin, HOMA-IR, lipid profile, inflammatory markers) appear in adults with obesity or metabolic syndrome, while effects in lean, metabolically healthy individuals are smaller. The authors flag practical issues — adherence over months, the early-fast hunger and irritability phase, and the lack of long-term outcome data — as the main barriers to clinical adoption rather than safety in healthy adults.

This 2019 meta-analysis pooled 26 double-blind randomized placebo-controlled trials of omega-3 PUFA supplementation for depression to ask a specific question: does the EPA-to-DHA ratio matter? The authors found that it does, decisively. Formulations that were either pure EPA or majority EPA (60 percent or more EPA) showed clinical benefit for depressive symptoms at relatively low doses (1 gram per day or less), while pure DHA and DHA-majority formulations did not. The therapeutic effect was specific to EPA-dominant supplementation. The mechanism inference is that EPA's anti-inflammatory effects (via resolvins and reduction of pro-inflammatory eicosanoids) drive the antidepressant signal, while DHA's role in neuronal membrane structure does not similarly translate to mood benefit at supplementation doses. The paper is the most-cited recent meta-analysis on omega-3 and depression and has shaped subsequent dosing recommendations: when omega-3 is used adjunctively for depressive disorders, EPA-dominant formulations at sub-gram doses are the evidence-supported choice. The paper does not claim omega-3 replaces antidepressant medication; it supports adjunctive use.

This review formalized the term "metabolic switch" — the transition from carbohydrate-derived energy to fatty-acid- and ketone-derived energy that occurs after liver glycogen stores are depleted, typically beyond about twelve hours of fasting depending on prior carbohydrate intake and activity. The authors synthesize the mechanistic literature on intermittent fasting protocols (alternate-day fasting, time-restricted feeding, periodic multi-day fasts) and argue that repeated engagement of this metabolic switch is what produces the adaptations associated with intermittent fasting: improvements in insulin sensitivity, lipid profile, blood pressure, inflammatory markers, and stress resistance. The review is positioned as a translational document for clinicians beginning to recommend intermittent fasting and emphasizes that the *frequency* of switching, not just the *duration* of any single fast, is plausibly the parameter that drives adaptation.

This Nature Reviews Neuroscience paper from Mark Mattson — the most cited researcher on fasting and brain health — synthesizes the case that periodic shifts between fed and fasted metabolic states are essential for optimal brain function. Mattson coined the term "intermittent metabolic switching" (IMS) for the pattern: eating depletes liver glycogen, fasting forces ketone production, and the cycle repeats. The review argues this oscillation is what humans evolved with, and that modern continuous-feeding patterns disrupt it with cognitive and neurological consequences. The mechanistic story focuses on β-hydroxybutyrate (BHB), which is transported into neuronal mitochondria as fuel but also acts as a signaling molecule. BHB induces brain-derived neurotrophic factor (BDNF), which promotes synaptic plasticity, neurogenesis in the hippocampus, and resistance to neuronal injury. Mattson reviews evidence connecting IMS to improved cognition, mood regulation, motor performance, autonomic-nervous-system function, and resistance to neurodegenerative disease. The framework has shaped subsequent fasting-and-brain-health research and is heavily cited in popular literature on fasting's cognitive benefits.

Open-access narrative review by DiNicolantonio and O'Keefe arguing that the marked increase in dietary linoleic acid (LA, the dominant omega-6 fatty acid in industrial seed oils) is a primary driver of coronary heart disease via the production of oxidized LDL particles enriched in oxidized linoleic acid metabolites (OXLAMs). The paper synthesizes evidence that LA intake has risen from roughly 1–2% of energy in the early 20th century to 8–10% today, that LA accumulates in adipose tissue with a half-life on the order of two years, and that oxidized LA species are inflammatory and atherogenic. The mechanism proposed: industrial vegetable oil consumption raises tissue LA, raises OXLAM production, and contributes to atheroma formation independent of cholesterol per se.

This is the most-cited review of whether fasting and calorie restriction actually trigger autophagy — the cellular self-cleaning process that recycles damaged proteins and organelles. The authors surveyed studies across cell culture, rodent models, and human subjects, looking at autophagy markers such as LC3 lipidation, p62 turnover, ATG7 expression, and mTOR signalling under various fasting and calorie-restriction protocols. Their headline conclusion is that fasting and calorie restriction reliably upregulate autophagy across a wide variety of tissues and organs — liver, muscle, brain, heart, kidney — and that the effect is robust. They also note that autophagy is mechanistically central to the longevity and disease-prevention benefits of caloric restriction: blocking autophagy in animal models attenuates those benefits. The evidence base, however, leans heavily on rodent and cell-culture work; direct measurement of autophagy in living humans is limited because most autophagy markers require tissue biopsy.

This Cell review by Saxton and David Sabatini — Sabatini being one of the original co-discoverers of mTOR — is the most-cited modern synthesis of mTOR signaling biology. The paper traces how mTOR (mechanistic target of rapamycin) integrates four classes of inputs: nutrients (amino acids, especially leucine and arginine), growth factors (insulin, IGF-1), cellular energy state (AMPK senses ATP:AMP), and stress signals. mTOR exists as two complexes: mTORC1, which controls protein synthesis, lipid synthesis, and inhibits autophagy; and mTORC2, which controls cytoskeletal organization and Akt phosphorylation. The review explains how mTORC1 activation drives anabolic programs (cell growth, protein synthesis) while suppressing catabolic programs (autophagy, lipolysis). Conversely, mTORC1 inhibition — by fasting, by rapamycin, by amino acid restriction, or by genetic loss — releases autophagy, increases lipolysis, and engages stress-resistance programs. The paper documents how dysregulated mTOR signaling drives cancer (mTOR is hyperactivated in most tumors), diabetes (mTORC1 contributes to insulin resistance), and aging (mTOR inhibition extends lifespan in every model organism tested). Therapeutic targeting of mTOR is an active drug-development area.

This randomized pilot study asked the cleanest possible head-to-head question for intermittent fasting: when matched for the goal of weight loss, does alternate-day fasting beat ordinary daily caloric restriction? Adults with obesity (BMI ≥30, age 18–55) were randomized to either zero-calorie alternate-day fasting (ADF, n=14) or moderate daily caloric restriction (CR at -400 kcal/day, n=12) for 8 weeks, followed by 24 weeks of unsupervised follow-up. The ADF arm achieved a substantially larger calculated energy deficit (about 376 kcal/day greater than CR), yet the actual weight loss was statistically indistinguishable: ADF -8.2 kg vs CR -7.1 kg over 8 weeks. Body composition, lipids, and insulin sensitivity index showed no significant between-group differences. Safety was strong — no adverse effects, 93 percent completion in the ADF arm. Twenty-four-week unsupervised follow-up showed similar weight regain in both groups, but the ADF arm trended toward more favorable lean-mass preservation. The honest conclusion: ADF is a safe and tolerable alternative to daily restriction with equivalent short-term outcomes, not a superior intervention.

This Cell Metabolism paper from Valter Longo's USC group introduced the fasting-mimicking diet (FMD) — a 5-day periodic dietary protocol designed to deliver fasting's molecular benefits while keeping participants able to consume modest amounts of plant-based food. The paper has two parts. In aged mice, monthly FMD cycles for several months produced multi-system regeneration: hippocampal neurogenesis rose, IGF-1 dropped, PKA activity decreased, NeuroD1 expression increased, and cognitive performance improved on standard mouse cognition tests. In a 38-participant pilot human RCT, three monthly FMD cycles (each 5 days) produced reductions in body weight, body fat, blood pressure, fasting glucose, and IGF-1 without significant adverse events. The paper is foundational because it bridged rodent CR research and practical human protocol design — providing a structured, safe framework for delivering fasting benefits without continuous calorie restriction. Longo subsequently commercialized the protocol as ProLon, a packaged 5-day FMD product. The paper's data quality is solid but the commercial development complicates how it should be cited.

This Canadian government laboratory study tested 52 canned fish products from the 2014 Canadian retail market for bisphenol A (BPA) and three related compounds (BPB, BPE, BPF) using gas chromatography mass spectrometry. The headline finding: BPA was detectable in every one of the 52 products, but at substantially lower levels than a comparable study from five years earlier. The concentration range was 0.96 to 265 nanograms per gram, with an average of 28 ng/g. Three of the four BPA analogues were essentially absent — BPB and BPE were not detected in any product, and BPF appeared in only four samples at low concentrations (1.8 to 5.7 ng/g) — suggesting BPA is still the dominant epoxy resin used in current can liners. The few outliers above 100 ng/g came from a single newly-marketed brand, indicating that brand-level differences in liner formulation drive most of the variation. Industry-wide, the data show measurable downward progress in canned-fish BPA exposure.

Quantitative review pooling adipose tissue fatty acid composition data from US-based studies across five decades. The authors document a near-linear rise in adipose linoleic acid (LA) from approximately 9.1% of total fatty acids in 1959 to 21.5% by 2008 — a 136% relative increase. The rise correlates strongly with dietary LA intake estimates over the same period (R² = 0.81). The paper also estimates an adipose LA incorporation half-life of approximately 680 days, meaning dietary changes take about two years of consistent intake to fully manifest in tissue composition. The data establishes that dietary LA is a major determinant of long-term tissue LA, and that tissue LA changes slowly enough that short-term dietary interventions show muted adipose effects.

This EFSA Scientific Committee statement weighs the cardiovascular and neurodevelopmental benefits of fish consumption against the risks of methylmercury exposure across the European population. It builds on EFSA's 2012 opinion which set the tolerable weekly intake (TWI) for methylmercury at 1.3 µg/kg body weight — meaning a 70 kg adult can safely consume about 91 µg/week. The 2015 statement identifies the dominant European mercury sources by species: tuna (the largest single contributor in adult diets), swordfish, cod, whiting, and pike. Notably, sardines are not on this high-mercury list. The statement acknowledges new epidemiological data (Seychelles cohort) showing that the long-chain omega-3s from fish may counteract some methylmercury toxicity — a benefit-risk tradeoff that favors lower-mercury species like sardines. EFSA's conclusion is risk-tiered: vulnerable groups (pregnant women, children, high-fish consumers up to 6× TWI) should choose lower-mercury species; the general adult population can consume fish at moderate intake without exceeding the TWI.

This study established a foundational point in microbiome research: dietary changes alter gut microbial composition rapidly and reproducibly. Ten participants alternated between an entirely animal-based diet (meat, eggs, cheese) and an entirely plant-based diet (grains, legumes, fruits, vegetables) for five days each. Microbiome composition shifted within 24 hours of dietary change and reverted within 48 hours of returning to baseline diet. The animal-based diet specifically increased the abundance of bile-tolerant microorganisms (Bilophila wadsworthia, Alistipes putredinis, Bacteroides) and decreased the abundance of Firmicutes that metabolize plant polysaccharides. Functional metagenomic analysis confirmed corresponding shifts in microbial gene expression. The paper is the canonical reference for the rapid-response biology of the human gut microbiome to dietary substrate change and for the bidirectional, plastic nature of these shifts.